Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070374 | 0.90 | — | — | |
| SCHEMBL4391948 | 0.87 | TSHR (0.36) | CA2CA9TSHR | |
| SCHEMBL21070519 | 0.83 | CA2 (0.37) | ODC1CA2CA9TSHR | |
| SCHEMBL17761118 | 0.82 | CA2 (0.33) | ODC1CA2CA9 | |
| SCHEMBL21441729 | 0.81 | CYP1A2 (0.35) | CA2CA9CYP3A4 | |
| SCHEMBL9585705 | 0.78 | CYP1A2 (0.39) | CA2CA9CYP3A4TSHR | |
| SCHEMBL22774840 | 0.78 | TSHR (0.47) | ODC1CYP3A4TSHR | |
| SCHEMBL10298223 | 0.78 | TSHR (0.47) | ODC1CYP3A4TSHR | |
| SCHEMBL128556 | 0.78 | — | — | |
| SCHEMBL64659 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11364246-B2 | Compounds | TMEM16A LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249970-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249970-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383988-A1 | Compounds | ENTERPRISE THERAPEUTICS HOLDINGS LIMITED (GB) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | ODC1 3053/4885CA2 2605/4885CA9 4134/4885 |
| US-11364246-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | ODC1 2401/4885CA2 156/4885CA9 1622/4885 |
| US-20200383988-A1 | Compounds | CACNA1E, TMEM109, CACNA1A | ODC1 2758/4885CA2 167/4885CA9 1596/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | ODC1 3053/4885CA2 2605/4885CA9 4134/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | ODC1 3053/4885CA2 2605/4885CA9 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.